Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | NA |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | arsenic trioxide | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | RT-PCR , Western blot , RIP etc. |
| Sample | human hepatocellular carcinoma cell lines(SMMC-7721, Huh7, MHCC97H, and HCCLM3), and one human liver cell line L02 |
| Expression Pattern | down-regulated |
| Function Description | PKM2 is upregulated, and MEG3 is downregulated in human hepatocellular carcinoma.Arsenic trioxide negatively regulated PKM2 and positively regulated MEG3.Arsenic trioxide inhibited the migration of HCC, but silencing MEG3 partially reversed this effect.On the other hand, the EMT-related biomarkers are alleviated under the treatment of arsenic trioxide, but this effect deteriorated when MEG3 is silenced.In conclusion, arsenic trioxide inhibits EMT in hepatocellular carcinoma by promoting lncRNA MEG3 and PKM2 negatively regulating MEG3. |
| Pubmed ID | 31003765 |
| Year | 2019 |
| Title | Arsenic Trioxide Inhibits EMT in Hepatocellular Carcinoma by Promoting lncRNA MEG3 via PKM2 |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |